Medivir
2.76
SEK
-1.08 %
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
-1.08%
+2.22%
-15.85%
-6.44%
-3.16%
-1.08%
-66.58%
-66.15%
-95.29%
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Read moreMarket cap
316.35M SEK
Turnover
90.78K SEK
Revenue
7.6M
EBIT %
-1,202.63 %
P/E
-
Dividend yield-%
-
Financial calendar
18.2
2025
Annual report '24
29.4
2025
Interim report Q1'25
7.5
2025
General meeting '24
ShowingAll content types
Medivir's CEO to BioStock: "The IND approval is a very important milestone"
Medivir obtains IND approval for fostrox - the first oral, liver-targeted treatment for advanced liver cancer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools